Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.
- DOI
- 10.1111/apt.70754
- Published
- 2026 Aug
- Container
- Alimentary pharmacology & therapeutics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/apt.70754,
title = {Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.},
author = {Kumada T and Atsukawa M and Arai T and Toyoda H and Tanaka J},
year = {2026},
journal = {Alimentary pharmacology \& therapeutics},
doi = {10.1111/apt.70754},
url = {https://doi.org/10.1111/apt.70754}
}RIS
TY - JOUR TI - Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply. AU - Kumada T AU - Atsukawa M AU - Arai T AU - Toyoda H AU - Tanaka J PY - 2026 JO - Alimentary pharmacology & therapeutics DO - 10.1111/apt.70754 UR - https://doi.org/10.1111/apt.70754 ER -
APA
T, K., M, A., T, A., H, T., & J, T. (2026). Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.. Alimentary pharmacology & therapeutics. https://doi.org/10.1111/apt.70754
Source records
- pubmed · retrieved 2026-09-26T05:29:00.439Z
- europe-pmc · retrieved 2026-09-26T05:29:00.470Z